Announcement PDF ASX ANNOUNCEMENT 14 March 2016 Anti-cancer Activities Recce Ltd is pleased to announce: 1. RECCE® antibiotic has demonstrated anticancer activities against each of 7 human cell lines of cancers: Leukaemia, stomach, intestine, breast, prostate, melanoma and kidney, in vitro tests conducted by an independent specialist laboratory in USA; 2. The Company has lodged a provisional patent application to protect its rights from these findings and its creative theories which are the logical basis of this development. These findings are illustrated in detail in the following table and graphs: Concentrations of Control and RECCE® antibiotic, respectively, over 3 days, giving 50% loss of cancer-cell activity Cancer Type Cell Line Leukaemia Stomach Intestine Breast Prostate Skin Melanoma Kidney MOLT-4 SNU-5 HCT116 MCF-7 DU-145 SK-MEL-2 TK-10 Tamoxifen Citrate 1 (%) 0.0001 0.0005 0.0008 0.0007 0.0008 0.0006 0.0006 RECCE® antibiotic (%) 0.0001 0.0006 0.0003 0.0005 0.001 0.0007 0.0006 1 Tamoxifen Citrate is a commercial human anti-cancer drug, used for Control and comparative purposes. In the following graphs, each illustrates the concentration of RECCE® antibiotic at which the respective cancers are rendered inactive (usually quite suddenly) by gradually increasing, but nevertheless, low concentrations of the antibiotic: MOLT-4 LEUKAEMIA CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.000032 0.0001 0.00032 0.001 0.0032 RECCE® Antibiotic Concentration (%) 0.01 SNU-5 STOMACH CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.00032 0.001 0.0032 0.01 0.032 0.1 RECCE® Antibiotic Concentration (%) HCT-116 INTESTINE CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.00032 0.001 0.0032 0.01 0.032 0.1 RECCE® Antibiotic Concentration (%) MCF7 BREAST CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.00032 0.001 0.0032 0.01 0.032 RECCE®Antibiotic Concentration (%) 0.1 DU-145 PROSTATE CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.00032 0.001 0.0032 0.01 0.032 0.1 RECCE® Antibiotic Concentration (%) SK-MEL-2 SKIN MELANOMA CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.00032 0.001 0.0032 0.01 0.032 0.1 RECCE® Antibiotic Concentration (%) TK-10 KIDNEY CANCER 120.0 Cell Activity (%) 100.0 80.0 60.0 40.0 20.0 0.0 0 0.00032 0.001 0.0032 0.01 0.032 0.1 RECCE® Antibiotic Concentration (%) Concentrations of RECCE® antibiotic described as successful above were additionally tested, and did not cause toxicity in normal human epithelial cells or Vero (monkey) cells. At any time, this finding would be considered to be of great potential medical importance – and even more so in this case, because antibiotic activity and anti-cancer activity are found in the same product. This emphasis is made since inflammation from prolonged bacterial activity is increasingly being associated with the propensity for cancer; the classic example is infection by Helicobacter pylori bacteria being strongly associated with inflammation and the subsequent development of cancer in the stomach and duodenum of the upper intestines of humans. Dr Graham Melrose, Executive Chairman of Recce Ltd, commented “Exciting as this finding is, it is cautioned that much work remains to confirm any relevance of these findings to the possibility of developing a commercial medical product. This development is part of Recce’s current, priority assessment of the range of potential markets which may be accessible through its patented polymer technology”. For further information please visit www.recce.com.au or contact: Investor Relations Peter Williams CFO & Company Secretary Recce Ltd Tel: +61 8 9253 9800 Media Communication Karen Oswald – karen.oswald@markocommunications.com.au Gary Buchholz – gary@markocommunications.com.au Marko Communications Tel: +61 423 602 353 About Recce Ltd Recce Ltd (ASX: RCE), led by Dr Graham Melrose, is a world-leader in synthetic-polymer antibiotics. RECCE® antibiotics have been synthesised by an extremely simple and economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes and the development of a pilot plant for flow-system manufacture of RECCE® antibiotics.